Compare ARDC & LFCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDC | LFCR |
|---|---|---|
| Founded | N/A | 1986 |
| Country | United States | United States |
| Employees | N/A | 382 |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 311.3M | 143.9M |
| IPO Year | 2011 | 1996 |
| Metric | ARDC | LFCR |
|---|---|---|
| Price | $11.99 | $3.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 127.0K | ★ 505.3K |
| Earning Date | 01-01-0001 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $557,559,000.00 |
| Revenue This Year | N/A | $2.32 |
| Revenue Next Year | N/A | $11.51 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $11.52 | $3.63 |
| 52 Week High | $15.03 | $8.98 |
| Indicator | ARDC | LFCR |
|---|---|---|
| Relative Strength Index (RSI) | 36.82 | 21.17 |
| Support Level | N/A | N/A |
| Resistance Level | $13.55 | $8.62 |
| Average True Range (ATR) | 0.17 | 0.42 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 47.50 | 7.61 |
Ares Dynamic Credit Allocation Fund Inc is a closed-ended, diversified management investment company. The fund's investment objective is to provide an attractive level of total return, through current income and, secondarily, through capital appreciation. The Fund invests in a broad, dynamically managed portfolio of senior secured loans (Senior Loans) made to companies whose debt is rated below investment grade; corporate bonds (Corporate Bonds) that are high yield issues rated below investment grade; other fixed-income instruments of a similar nature that may be represented by derivatives; and securities of collateralized loan obligations (CLOs).
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.